Related references
Note: Only part of the references are listed.Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets
Rong Li et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Integrated analysis and network pharmacology approaches to explore key genes of Xingnaojing for treatment of Alzheimer's disease
Meixia Wang et al.
BRAIN AND BEHAVIOR (2020)
Comprehensive chemical profiling of Jia-Wei-Qi-Fu-Yin and its network pharmacology-based analysis on Alzheimer's disease
Hai-Ming An et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2020)
A graph-embedded deep feedforward network for disease outcome classification and feature selection using gene expression data
Yunchuan Kong et al.
BIOINFORMATICS (2018)
Automated detection of driver fatigue based on EEG signals using gradient boosting decision tree model
Jianfeng Hu et al.
COGNITIVE NEURODYNAMICS (2018)
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma
Dan-dan Xiong et al.
CLINICAL DRUG INVESTIGATION (2018)
Effects of curcuminoids identified in rhizomes of Curcuma longa on BACE-1 inhibitory and behavioral activity and lifespan of Alzheimer's disease Drosophila models
Xue Wang et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2014)
A Network Pharmacology Study of Chinese Medicine QiShenYiQi to Reveal Its Underlying Multi-Compound, Multi-Target, Multi-Pathway Mode of Action
Xiang Li et al.
PLOS ONE (2014)
Proteoglycans in the central nervous system: Role in development, neural repair, and Alzheimer's disease
Hao Cui et al.
IUBMB LIFE (2013)
A knowledge-based framework for creative conceptual design of multi-disciplinary systems
Yong Chen et al.
COMPUTER-AIDED DESIGN (2012)
Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking
Michael M. Mysinger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Network analyses in systems pharmacology
Seth I. Berger et al.
BIOINFORMATICS (2009)
Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade
Yuki Takada-Takatori et al.
NEUROPHARMACOLOGY (2006)
Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease
HX Dong et al.
PSYCHOPHARMACOLOGY (2005)
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease
DR Liston et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Awareness of cognitive deficits and behavioural abnormalities amongst patients with Alzheimer's disease
OP Almeida et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2000)
Share Paper
